Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Antonio CurtiRoberto M Lemoli

Abstract

In acute myeloid leukemia (AML), alloreactive natural killer (NK) cells are crucial mediators of immune responses after haploidentical stem cell transplantation. Allogeneic NK cell infusions have been adoptively transferred with promising clinical results. We aimed at determining whether the composition of NK graft in terms of frequency of alloreactive NK cells influence the clinical response in a group of elderly AML patients undergoing NK immunotherapy. Seventeen AML patients, in first complete remission (CR; median age 64 years, range 53-73) received NK cells from haploidentical KIR-ligand-mismatched donors after fludarabine/cyclophosphamide chemotherapy, followed by IL2. To correlate donor NK cell activity with clinical response, donor NK cells were assessed before and after infusion. Toxicity was moderate, although 1 patient died due to bacterial pneumonia and was censored for clinical follow-up. With a median follow-up of 22.5 months (range, 6-68 months), 9 of 16 evaluable patients (0.56) are alive disease-free, whereas 7 of 16 (0.44) relapsed with a median time to relapse of 9 months (range, 3-51 months). All patients treated with molecular disease achieved molecular CR. A significantly higher number of donor alloreactiv...Continue Reading

References

Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Sep 3, 2004·Current Opinion in Immunology·Lorenzo Moretta, Alessandro Moretta
Dec 21, 2004·Molecular Immunology·Karl-Johan MalmbergHans-Gustaf Ljunggren
Dec 21, 2005·Blood Reviews·Sherif S Farag, Michael A Caligiuri
Jul 26, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Katharine C HsuUNKNOWN International Histocompatibility Working Group
Oct 31, 2006·Journal of Translational Medicine·A BontadiniR Conte
Sep 2, 2008·Immunological Reviews·Alessandro MorettaLorenzo Moretta
Oct 7, 2008·Oncogene·I Waldhauer, A Steinle
Oct 23, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Cyril FauriatKarl-Johan Malmberg
Jan 20, 2009·Leukemia·R WillemzeUNKNOWN Eurocord-Netcord and Acute Leukaemia Working Party of the EBMT
Nov 3, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Dianne De SantisCampbell S Witt
Jan 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey E RubnitzWing Leung
Sep 8, 2010·Nature Reviews. Immunology·Petter Höglund, Petter Brodin
Dec 18, 2012·British Journal of Haematology·Yishai Ofran, Jacob M Rowe

❮ Previous
Next ❯

Citations

Jun 3, 2016·Expert Review of Anticancer Therapy·Nicole A P LiebermanCourtney A Crane
Aug 18, 2016·Cancer Immunology, Immunotherapy : CII·Raquel TarazonaRafael Solana
Mar 16, 2018·Future Oncology·Amanda PrzespolewskiEunice S Wang
Aug 30, 2017·International Journal of Molecular Sciences·Beatriz Martín-AntonioAlvaro Urbano-Ispizua
Nov 18, 2017·Oncoimmunology·Carole FournierLionel Apetoh
Jan 11, 2019·Leukemia & Lymphoma·Hongbing MaYuping Gong
Aug 18, 2017·Current Opinion in Hematology·Kate Stringaris, Austin J Barrett
Feb 26, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nathaniel J ButeynSusheela Tridandapani
Jan 13, 2018·Expert Review of Neurotherapeutics·Nicole A P LiebermanCourtney A Crane
Apr 14, 2017·Frontiers in Immunology·Silvia Lopez-Lastra, James P Di Santo
Apr 20, 2017·Frontiers in Immunology·Clair M Gardiner, David K Finlay
Mar 21, 2020·Cancers·Aline Pfefferle, Nicholas D Huntington
Nov 30, 2016·Frontiers in Immunology·Christian ChabannonBoris Calmels
Sep 1, 2019·International Journal of Molecular Sciences·Peter ValentDominik Wolf
Dec 24, 2019·Frontiers in Immunology·Paola MinettoEmanuela Marcenaro
Jun 2, 2020·Frontiers in Immunology·Aline PfefferleKarl-Johan Malmberg
Feb 5, 2019·Oncoimmunology·Aroa Baragaño RanerosBeatriz Suárez-Álvarez
Oct 19, 2019·Journal of Clinical Medicine·Simona SivoriDaniela Pende
Dec 9, 2020·Journal of Hematology & Oncology·Jing Xu, Ting Niu
Jun 24, 2017·Cancer Immunology Research·Lisa L LiuKarl-Johan Malmberg
Feb 24, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miguel Lopez-Botet, Aura Muntasell
Oct 28, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·JongBok LeeLi Zhang
Feb 16, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andreas T BjörklundKarl-Johan Malmberg
Mar 11, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Harry DolstraNicolaas M Schaap
Aug 18, 2020·Molecular Aspects of Medicine·Simona SivoriLorenzo Moretta
Jan 4, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kentaro IdoHirohisa Nakamae

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.